The University of Chicago Header Logo

Connection

Christopher M. Gomez to Aged

This is a "connection" page, showing publications Christopher M. Gomez has written about Aged.
Connection Strength

0.323
  1. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
    View in: PubMed
    Score: 0.041
  2. Longitudinal cerebral blood flow changes during speech in hereditary ataxia. Brain Lang. 2010 Jul; 114(1):43-51.
    View in: PubMed
    Score: 0.026
  3. Evaluation of sleep and daytime somnolence in spinocerebellar ataxia type 6 (SCA6). Neurology. 2006 May 09; 66(9):1430-1.
    View in: PubMed
    Score: 0.020
  4. Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6. Ann Neurol. 2005 Mar; 57(3):349-54.
    View in: PubMed
    Score: 0.018
  5. Novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits. Ann Neurol. 2003 Dec; 54(6):725-31.
    View in: PubMed
    Score: 0.017
  6. Spinocerebellar ataxia in monozygotic twins. Arch Neurol. 2002 Dec; 59(12):1945-51.
    View in: PubMed
    Score: 0.016
  7. The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3. Parkinsonism Relat Disord. 2020 03; 72:37-43.
    View in: PubMed
    Score: 0.013
  8. Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor. Cerebellum. 2019 Jun; 18(3):519-526.
    View in: PubMed
    Score: 0.012
  9. Targeted exome analysis identifies the genetic basis of disease in over 50% of patients with a wide range of ataxia-related phenotypes. Genet Med. 2019 01; 21(1):195-206.
    View in: PubMed
    Score: 0.012
  10. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann Neurol. 2018 04; 83(4):816-829.
    View in: PubMed
    Score: 0.011
  11. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann Neurol. 1997 Dec; 42(6):933-50.
    View in: PubMed
    Score: 0.011
  12. The Initial Symptom and Motor Progression in Spinocerebellar Ataxias. Cerebellum. 2017 06; 16(3):615-622.
    View in: PubMed
    Score: 0.011
  13. Depression and clinical progression in spinocerebellar ataxias. Parkinsonism Relat Disord. 2016 Jan; 22:87-92.
    View in: PubMed
    Score: 0.010
  14. Early Cerebellar Network Shifting in Spinocerebellar Ataxia Type 6. Cereb Cortex. 2016 07; 26(7):3205-18.
    View in: PubMed
    Score: 0.009
  15. Cerebrospinal Fluid Biomarkers in Spinocerebellar Ataxia: A Pilot Study. Dis Markers. 2015; 2015:413098.
    View in: PubMed
    Score: 0.009
  16. Coenzyme Q10 and spinocerebellar ataxias. Mov Disord. 2015 Feb; 30(2):214-20.
    View in: PubMed
    Score: 0.009
  17. Analysis of the visual system in Friedreich ataxia. J Neurol. 2013 Sep; 260(9):2362-9.
    View in: PubMed
    Score: 0.008
  18. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol. 2012 Apr; 71(4):487-97.
    View in: PubMed
    Score: 0.008
  19. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. Int Urol Nephrol. 2012 Feb; 44(1):91-7.
    View in: PubMed
    Score: 0.007
  20. Speech characteristics associated with three genotypes of ataxia. J Commun Disord. 2011 Jul-Aug; 44(4):478-92.
    View in: PubMed
    Score: 0.007
  21. What is the predictive value of urodynamics to reproduce clinical findings of urinary frequency, urge urinary incontinence, and/or stress urinary incontinence? Int Urogynecol J. 2010 Oct; 21(10):1205-9.
    View in: PubMed
    Score: 0.007
  22. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010 Mar 15; 25(4):426-32.
    View in: PubMed
    Score: 0.007
  23. Survival disparities among African American women with invasive bladder cancer in Florida. Cancer. 2009 Sep 15; 115(18):4196-209.
    View in: PubMed
    Score: 0.006
  24. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006 Jun 13; 66(11):1711-6.
    View in: PubMed
    Score: 0.005
  25. Depth perception in cerebellar and basal ganglia disease. Exp Brain Res. 2006 Oct; 175(1):165-76.
    View in: PubMed
    Score: 0.005
  26. Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation. Mol Cell Neurosci. 2006 May-Jun; 32(1-2):82-90.
    View in: PubMed
    Score: 0.005
  27. Deficits in ocular and manual tracking due to episodic ataxia type 2. Mov Disord. 2004 Jul; 19(7):778-787.
    View in: PubMed
    Score: 0.004
  28. Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia. Brain. 2003 Oct; 126(Pt 10):2312-22.
    View in: PubMed
    Score: 0.004
  29. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989 Sep; 26(3):404-7.
    View in: PubMed
    Score: 0.002
  30. Memory impairment in patients with progressive supranuclear palsy. Arch Neurol. 1989 Jul; 46(7):765-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.